In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery

References

• Abbott NJ. 2013. Blood–brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 36(3):437–449.
   PubMed Web of Science ®Google Scholar
• Adebileje T, Valizadeh A, Amani A. 2017. Effect of formulation parameters on the size of PLGA nanoparticles encapsulating bovine serum albumin: a response surface methodology. J Contemp Med Sci. 3(12):306–312.
   Web of Science ®Google Scholar
• Aricioglu F, Yigit G. 2015. Pharmacological treatment approach for Parkinson’s diseases in today and the future. MUSBED. 5(4):1.
   Google Scholar
• Barwal I, Sood A, Sharma M, Singh B, Yadav SC. 2013. Development of stevioside Pluronic-F-68 copolymer based PLA-nanoparticles as an antidiabetic nanomedicine. Colloids Surf, B. 101:510–516.
   PubMed Web of Science ®Google Scholar
• Betarbet R, Sherer TB, Greenamyre JT. 2002. Animal models of Parkinson’s disease. Bioessays. 24(4):308–318.
   PubMed Web of Science ®Google Scholar
• Blesa J, Lanciego JL, Obeso JA. 2015. Parkinson’s disease: cell vulnerability and disease progression. Front Neuroanat. 9:125.
   PubMed Web of Science ®Google Scholar
• Brime B, Ballesteros M, Frutos P. 2000. Preparation and in vitro characterization of gelatin microspheres containing Levodopa for nasal administration. J Microencapsul. 17(6):777–784.
   PubMed Web of Science ®Google Scholar
• Budhian A, Siegel SJ, Winey KI. 2007. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm. 336(2):367–375.
   PubMed Web of Science ®Google Scholar
• Cakmur R. 2011. Parkinson Hastalığı ve Medikal Tedavisi. Klinik Gelişim. 23(1):53–61.
   Google Scholar
• Chesselet M-F, Richter F. 2011. Modelling of Parkinson’s disease in mice. Lancet Neurol. 10(12):1108–1118.
   PubMed Web of Science ®Google Scholar
• Choudhary H, Agrawal A, Malviya R, Yadav S, Jaliwala Y, Patil U. 2010. Evaluation and optimization of preparative variables for controlled-release floating microspheres of levodopa/carbidopa. Die Pharmazie. 65(3):194–198.
   PubMed Web of Science ®Google Scholar
• Cortesi R, Esposito E, Drechsler M, Pavoni G, Cacciatore I, Sguizzato M, Di Stefano A. 2017. L-dopa co-drugs in nanostructured lipid carriers: a comparative study. Mater Sci Eng C Mater Biol Appl. 72:168–176.
   PubMed Web of Science ®Google Scholar
• Feczkó T, Tóth J, Dósa G, Gyenis J. 2011. Influence of process conditions on the mean size of PLGA nanoparticles. Chem Eng Process. 50(8):846–853.
   Web of Science ®Google Scholar
• Feczkó T, Tóth J, Gyenis J. 2008. Comparison of the preparation of PLGA–BSA nano-and microparticles by PVA, poloxamer and PVP. Colloids Surf A. 319(1-3):188–195.
   Google Scholar
• Gabathuler R. 2010. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis. 37(1):48–57.
   PubMed Web of Science ®Google Scholar
• Gambaryan P, Kondrasheva I, Severin E, Guseva A, Kamensky A. 2014. Increasing the efficiency of Parkinson’s disease treatment using a poly (lactic-co-glycolic acid)(PLGA) based L-DOPA delivery system. Exp Neurobiol. 23(3):246–252.
   PubMedGoogle Scholar
• Gao H. 2016. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharmaceutica Sinica B. 6(4):268–286.
   PubMed Web of Science ®Google Scholar
• Gao X, Tao W, Lu W, Zhang Q, Zhang Y, Jiang X, Fu S. 2006. Lectin-conjugated PEG–PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials. 27(18):3482–3490.
   PubMed Web of Science ®Google Scholar
• Garbayo E, Ansorena E, Blanco-Prieto MJ. 2013. Drug development in Parkinson’s disease: from emerging molecules to innovative drug delivery systems. Maturitas. 76(3):272–278.
   PubMed Web of Science ®Google Scholar
• Hurtig HI. 1997. Problems with current pharmacologic treatment of Parkinson's disease. Exp Neurol. 144(1):10–16.
   PubMed Web of Science ®Google Scholar
• Illum L. 2003. Nasal drug delivery—possibilities, problems and solutions. J Control Release. 87(1-3):187–198.
   PubMed Web of Science ®Google Scholar
• Karanth H, Murthy R. 2008. Nanotechnology in brain targeting. Int J Pharm Sci Nanotechnol. 1(1):9–34.
   Google Scholar
• Khan AR, Liu M, Khan MW, Zhai G. 2017. Progress in brain targeting drug delivery system by nasal route. J Control Release. 268:364–389.
   PubMed Web of Science ®Google Scholar
• Kim TK, Kang W, Chun IK, Oh SY, Lee YH, Gwak HS. 2009. Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. Eur J Pharm Sci. 38(5):525–532.
   PubMed Web of Science ®Google Scholar
• Kondrasheva IG, Antipova TA, Barsegyan GG, Gambaryan PY, Guseva AA, Kamensky AA. 2012. Efficacy and safety of nasal administration of “Na-no-L-DOPA” based on PLGA nanoparticles. Engineering. 04(10):27–29.
   Google Scholar
• Kumar R, Singh A, Sharma K, Dhasmana D, Garg N, Siril PF. 2020. Preparation, characterization and in vitro cytotoxicity of fenofibrate and nabumetone loaded solid lipid nanoparticles. Mater Sci Eng C. 106:110184.
   PubMed Web of Science ®Google Scholar
• Kumar R, Siril PF. 2015. Controlling the size and morphology of griseofulvin nanoparticles using polymeric stabilizers by evaporation-assisted solvent–antisolvent interaction method. J Nanopart Res. 17(6):256.
   Web of Science ®Google Scholar
• Kura AU, Ain NM, Hussein MZ, Fakurazi S, Hussein-Al-Ali SH. 2014. Toxicity and metabolism of layered double hydroxide intercalated with levodopa in a Parkinson’s disease model. IJMS. 15(4):5916–5927.
   Google Scholar
• Kura AU, Hussein Al Ali SH, Hussein MZ, Fakurazi S, Arulselvan P. 2013. Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. Int J Nanomed. 8:1103–1110.
   PubMed Web of Science ®Google Scholar
• Kura AU, Hussein-Al-Ali SH, Hussein MZ, Fakurazi S. 2014. Preparation of Tween 80-Zn/Al-levodopa-layered double hydroxides nanocomposite for drug delivery system. Scientif World J. 2014:1–10.
   Google Scholar
• Leyva-Gomez G, Cortes H, Magana JJ, Leyva-Garcia N, Quintanar-Guerrero D, Floran B. 2015. Nanoparticle technology for treatment of Parkinson’s disease: the role of surface phenomena in reaching the brain. Drug Discov Today. 20(7):824–837.
   PubMed Web of Science ®Google Scholar
• Liu Q, Shao X, Chen J, Shen Y, Feng C, Gao X, Zhao Y, Li J, Zhang Q, Jiang X. 2011. In vivo toxicity and immunogenicity of wheat germ agglutinin conjugated poly (ethylene glycol)-poly (lactic acid) nanoparticles for intranasal delivery to the brain. Toxicol Appl Pharmacol. 251(1):79–84.
   PubMed Web of Science ®Google Scholar
• Luinstra M, Grasmeijer F, Hagedoorn P, Moes JR, Frijlink HW, de Boer AH. 2015. A levodopa dry powder inhaler for the treatment of Parkinson’s disease patients in off periods. Eur J Pharm Biopharm. 97(Pt A):22–29.
   PubMedGoogle Scholar
• Mainardes RM, Evangelista RC. 2005. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 290(1-2):137–144.
   PubMedGoogle Scholar
• Maleki H, Dorkoosh F, Adabi M, Khosravani M, Arzani H, Kamali M. 2017. Methotrexate-loaded plga nanoparticles: preparation, characterization and their cytotoxicity effect on human glioblastoma U87MG cells. Int J Med Nano Res. 4(1):020.
   Google Scholar
• Masserini M. 2013. Nanoparticles for brain drug delivery. ISRN Biochem. 2013:1–18.
   Google Scholar
• McCall RL, Sirianni RW. 2013. PLGA nanoparticles formed by single- or double-emulsion with vitamin E-TPGS. J Vis Exp. (82):51015.
   PubMed Web of Science ®Google Scholar
• Meredith GE, Rademacher DJ. 2011. MPTP mouse models of Parkinson’s disease: an update. J Parkinsons Dis. 1(1):19–33.
   PubMedGoogle Scholar
• Mistry A, Stolnik S, Illum L. 2009. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 379(1):146–157.
   PubMed Web of Science ®Google Scholar
• Mo Y, Lim LY. 2004. Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 Cells. J Pharm Sci. 93(1):20–28.
   PubMed Web of Science ®Google Scholar
• Mohanraj K, Sethuraman S, Krishnan UM. 2013. Development of poly(butylene succinate) microspheres for delivery of levodopa in the treatment of Parkinson's disease. J Biomed Mater Res B Appl Biomater. 101(5):840–847.
   PubMedGoogle Scholar
• Özsoy Y. 2007. Administration of drug via nasal route. J Faculty Pharmacy Ankara. 36(4):83–267.
   Google Scholar
• PD Med Collaborative Group; Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. 2014. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. The Lancet. 384(9949):1196–1205.
   PubMed Web of Science ®Google Scholar
• Pires PC, Santos AO. 2018. Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies. J Control Release. 270:89–100.
   PubMed Web of Science ®Google Scholar
• Pooja D, Tunki T, Kulhari H, Reddy BB, Sistla R. 2015. Characterization, biorecognitive activity and stability of WGA grafted lipid nanostructures for the controlled delivery of Rifampicin. Chem Phys Lipids. 193:11–17.
   PubMed Web of Science ®Google Scholar
• Portaccio M, Menale C, Diano N, Serri C, Mita DG, Lepore M. 2015. Monitoring production process of cisplatin-loaded PLGA nanoparticles by FT-IR microspectroscopy and univariate data analysis. J Appl Polym Sci. 132(3):1–9.
   PubMed Web of Science ®Google Scholar
• Sadigh-Eteghad S, Talebi M, Farhoudi M, Mahmoudi J, Reyhani B. 2013. Effects of Levodopa loaded chitosan nanoparticles on cell viability and caspase-3 expression in PC12 neural like cells. Neurosciences. 18(3):281–283.
   Web of Science ®Google Scholar
• Seju U, Kumar A, Sawant K. 2011. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater. 7(12):4169–4176.
   PubMed Web of Science ®Google Scholar
• Sharma S, Lohan S, Murthy R. 2014. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm. 40(7):869–878.
   PubMed Web of Science ®Google Scholar
• Shin M, Kim HK, Lee H. 2014. Dopamine‐loaded poly (d, l‐lactic‐co‐glycolic acid) microspheres: New strategy for encapsulating small hydrophilic drugs with high efficiency. Biotechnol Progress. 30(1):215–223.
   PubMed Web of Science ®Google Scholar
• Wang X, Chi N, Tang X. 2008. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm. 70(3):735–740.
   PubMed Web of Science ®Google Scholar
• Wang C, Ho PC, Lim LY. 2010. Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells. Int J Pharm. 400(1-2):201–210.
   PubMed Web of Science ®Google Scholar
• Weissenbock A, Wirth M, Gabor F. 2004. WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells. J Control Release. 99(3):383–392.
   PubMed Web of Science ®Google Scholar
• Wen Z, Yan Z, Hu K, Pang Z, Cheng X, Guo L, Zhang Q, Jiang X, Fang L, Lai R. 2011. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson’s disease following intranasal administration. J Control Release. 151(2):131–138.
   PubMed Web of Science ®Google Scholar
• Yang X, Zheng R, Cai Y, Liao M, Yuan W, Liu Z. 2012. Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. Int J Nanomed. 7:2077–2086.
   PubMed Web of Science ®Google Scholar
• Zeini D, Khoshkenar P, Rabiee M. 2012. The influence of formulation and process parameters on the morphology, size and release profile of L-dopa-loaded poly lactic-co-glycolic acid (PLGA) microspheres. Open Conf Proc J. 3:1–7.
   Google Scholar
• Zhou YZ, Alany RG, Chuang V, Wen J. 2013. Optimization of PLGA nanoparticles formulation containing L-DOPA by applying the central composite design. Drug Dev Ind Pharm. 39(2):321–330.
   PubMed Web of Science ®Google Scholar
• Zweers ML, Grijpma DW, Engbers GH, Feijen J. 2003. The preparation of monodisperse biodegradable polyester nanoparticles with a controlled size. J Biomed Mater Res. 66(2):559–566.
   Google Scholar